Two Sigma Advisers’s Intellia Therapeutics NTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$19.6M Buy
2,093,017
+110,700
+6% +$1.04M 0.04% 340
2025
Q1
$14.1M Sell
1,982,317
-16,000
-0.8% -$114K 0.03% 433
2024
Q4
$23.3M Buy
1,998,317
+970,700
+94% +$11.3M 0.05% 277
2024
Q3
$21.1M Buy
1,027,617
+257,700
+33% +$5.3M 0.05% 312
2024
Q2
$17.2M Buy
769,917
+110,600
+17% +$2.48M 0.04% 377
2024
Q1
$18.1M Buy
659,317
+195,300
+42% +$5.37M 0.04% 368
2023
Q4
$14.1M Buy
464,017
+210,400
+83% +$6.42M 0.03% 416
2023
Q3
$8.02M Sell
253,617
-24,600
-9% -$778K 0.02% 552
2023
Q2
$11.3M Sell
278,217
-257,700
-48% -$10.5M 0.03% 451
2023
Q1
$20M Sell
535,917
-46,300
-8% -$1.73M 0.05% 332
2022
Q4
$20.3M Sell
582,217
-1,700
-0.3% -$59.3K 0.06% 335
2022
Q3
$32.7M Sell
583,917
-131,300
-18% -$7.35M 0.09% 220
2022
Q2
$37M Buy
715,217
+277,200
+63% +$14.3M 0.11% 205
2022
Q1
$31.8M Buy
438,017
+167,300
+62% +$12.2M 0.08% 229
2021
Q4
$32M Buy
270,717
+100,800
+59% +$11.9M 0.08% 214
2021
Q3
$22.8M Sell
169,917
-240,300
-59% -$32.2M 0.06% 285
2021
Q2
$66.4M Sell
410,217
-269,500
-40% -$43.6M 0.18% 118
2021
Q1
$54.6M Buy
679,717
+139,200
+26% +$11.2M 0.15% 142
2020
Q4
$29.4M Buy
540,517
+83,900
+18% +$4.56M 0.08% 259
2020
Q3
$9.08M Buy
456,617
+127,300
+39% +$2.53M 0.03% 567
2020
Q2
$6.92M Buy
329,317
+72,400
+28% +$1.52M 0.02% 683
2020
Q1
$3.14M Buy
256,917
+25,000
+11% +$306K 0.01% 891
2019
Q4
$3.4M Buy
231,917
+93,500
+68% +$1.37M 0.01% 995
2019
Q3
$1.85M Buy
138,417
+40,800
+42% +$545K ﹤0.01% 1142
2019
Q2
$1.6M Buy
97,617
+62,100
+175% +$1.02M ﹤0.01% 1312
2019
Q1
$607K Buy
35,517
+14,400
+68% +$246K ﹤0.01% 1722
2018
Q4
$288K Buy
+21,117
New +$288K ﹤0.01% 2001